anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Use of an isolated resinoid extract of Myoporum crassifoliumor a fraction of resinoid extract of Myoporum crassifolium, comprising as main compound of (-)-epi-alpha -bisabolol, less than 1% of (-)-alpha -bisabolol, and substantially free of the presence of foul smelling degradation products, preferably resulting from e.g. the thermolysis of wood and oxidative degradation of polyunsaturated fatty acids, for preparing a cosmetic or a pharmaceutical composition for the prevention and treatment of skin disorders related to the skin inflammation, is claimed. Use of an isolated resinoid extract of Myoporum crassifoliumor a fraction of resinoid extract of Myoporum crassifolium, comprising as main compound of (-)-epi-alpha -bisabolol, less than 1% of (-)-alpha -bisabolol, substantially free of the presence of foul smelling degradation products, preferably resulting from the thermolysis of wood, oxidative degradation of polyunsaturated fatty acids, or thermal degradation of sesquiterpene substances, such as mesityl oxide, 1-acetyl-4-methyl-3-cyclohexene and 4-methylacetophenone, for preparing a cosmetic or a pharmaceutical composition for the prevention and treatment of skin disorders related to the skin inflammation, is claimed. Independent claims are included for: (1) the composition substantially free of the presence of foul smelling degradation products comprising Myoporum crassifoliumresinoid extract or a fraction of the resinoid extract of Myoporum crassifolium(0.01-10 (preferably 0.5-3) wt.%), comprising (-)-epi-alpha -bisabolol (30-99 (preferably 50-60) wt.%); and (2) extraction process of a resinoid substantially free of the presence of degradation products, from a raw material containing the resinoid substances or a precursor, preferably Myoporum crassifolium, comprising: (d) contacting a sample of Myoporum crassifoliumwith a fluorohydrocarbon sample, preferably 1,1,1,2-tetrafluoro-ethane in an extractor; (e) continuous extraction of the resinoid extract; and (f) recovering the resinoid extract. ACTIVITY : Antiinflammatory; Dermatological; Vulnerary; Antiseborrheic; Antipruritic; Antipsoriatic. MECHANISM OF ACTION : None given.
The invention pertains to the technical field of medicine and discloses a preparation method of ceftazidime crystal compound for treating surgical infection. The structure of the ceftazidime crystal compound is shown as the formula (I). The crystal compound is measured by powder X-ray diffractometry. The X-ray powder diffraction pattern at a diffraction angle of 2Theta+-0.2o is shown in. 1. The The prepared ceftazidime crystal compound has high purity, low pyridine and polymer content, and good stability. It is not easy to absorb moisture, has good fluidity, and greatly improves its solubility.
An automatic adjustable supporting equipment, including a supporting band, an adjusting device, and a controller, is provided. The supporting band wraps around a limb of a user. The adjusting device is disposed on the supporting band, and includes an actuating mechanism and an accelerometer. The actuating mechanism is configured to adjust a pressure applied on the limb by the supporting band. The accelerometer is configured to detect an acceleration value. The controller is coupled to adjusting device, and is configured to drive the actuating mechanism to adjust the pressure to a preset pressure value according to the acceleration value.
Both peripheral and central corticotropin-releasing factor (CRF) systems have been implicated in regulating pain sensation. However, compared with the peripheral, the mechanisms underlying central CRF system in pain modulation have not yet been elucidated, especially at the neural circuit level. The corticoaccumbal circuit, a structure rich in CRF receptors and CRF-positive neurons, plays an important role in behavioral responses to stressors including nociceptive stimuli. The present study was designed to investigate whether and how CRF signaling in this circuit regulated pain sensation under physiological and pathological pain conditions. Our studies employed the viral tracing and circuit-, and cell-specific electrophysiological methods to label the CRF-containing circuit from the medial prefrontal cortex to the nucleus accumbens shell (mPFCCRF-NAcS) and record its neuronal propriety. Combining optogenetic and chemogenetic manipulation, neuropharmacological methods, and behavioral tests, we were able to precisely manipulate this circuit and depict its role in regulation of pain sensation. The current study found that the CRF signaling in the NAc shell (NAcS), but not NAc core, was necessary and sufficient for the regulation of pain sensation under physiological and pathological pain conditions. This process was involved in the CRF-mediated enhancement of excitatory synaptic transmission in the NAcS. Furthermore, we demonstrated that the mPFCCRF neurons monosynaptically connected with the NAcS neurons. Chronic pain increased the protein level of CRF in NAcS, and then maintained the persistent NAcS neuronal hyperactivity through enhancement of this monosynaptic excitatory connection, and thus sustained chronic pain behavior. These findings reveal a novel cell- and circuit-based mechanistic link between chronic pain and the mPFCCRF → NAcS circuit and provide a potential new therapeutic target for chronic pain.
A method for mitigating the risk of providing improper infusion dosages to patients is provided. The method is performed by an infusion safety server which includes a processor, a server memory, and a server database. The method includes receiving an initiation instruction from a clinician computer system to begin a safety check process. The initiation instruction includes a set of prescribed infusion parameters. The method includes instructing a patient computer system to transmit a resolution message including a set of resolution infusion parameters, within a predetermined timeout period. The method includes transmitting a timeout alert to a support computer system if the resolution message is not received within the predetermined timeout period. The method includes transmitting an infusion safety alert to the support computer system if the set of resolution infusion parameters is determined to not match the set of prescribed infusion parameters.
Endovascular treatment will be performed within 6 weeks of randomization, according to standards of practice, and under general anaesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling or stents, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
Although the effect of early childhood stress on central nervous pain processing is well known, studies on the association of prematurity and chronic pain are scarce. This study used data from a single-centre retrospective cohort study followed by a prospective clinical examination and pain assessment. The study was based on data from the local birth registry. Newborns born between 1969 and 2002 who had reached adulthood were eligible .. Using a selection algorithm, a study cohort stratified by gestational age (GA) was recruited. Chronic pain conditions were assessed using questionnaire and standardized pain drawings. Data on the pre-, peri- and postnatal clinical course was assessed from medical records. Multivariable logistic regression analyses were conducted to investigate associations between prematurity and chronic pain with adjustment for age, gender, socioeconomic status, and perinatal stress factors. 427 participants born preterm and full-term were included (age 28.5 ± 8.7 years). Chronic pain conditions were similarly common between groups with different levels of prematurity (GA ≥ 37 weeks: 34.5 %, GA33-36 weeks: 37.6 %, GA32-29 weeks: 25.2 %, GA < 29 weeks: 30.4 %, p = 0.20). In multivariable analyses, no association between low GA and the presence of chronic pain was found (OR = 0.99 (CI95 %: 0.94-1.04, p = 0.63); this was also true for a subanalysis of widespread pain. While neither fetal nutritional status nor perinatal stressors were associated with pain, exposure to maternal but not paternal smoking during pregnancy was associated with increased risk to develop pain (OR = 2.77 (CI95 %: 1.31-5.88, p = 0.008) in adults born preterm and full-term. This study suggests that prematurity by itself does not increase the risk of chronic pain later in life, but provides preliminary evidence for maternal smoking during pregnancy as risk factor.
The term 'liquid biopsy' has become widely used by clinicians with the development of non-invasive diagnostic and monitoring techniques for malignancies. Liquid biopsy can provide genetic information for early diagnosis, risk stratification, treatment selection and postoperative follow-up. In the era of personalized medicine, liquid biopsy is an important research direction. In recent years, research on circulating tumour DNA (ctDNA) in hematological malignancies has also made great progress. This review provides an overview of the current understanding of circulating tumour DNA in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Additionally, recent advancements in the monitoring of minimal/measurable residual disease (MRD) through ctDNA are discussed.
PROBLEM TO BE SOLVED: To obtain an antiosteoporotic agent free from adverse effects such as decrease of appetite by including fish scale powder as an active ingredient. SOLUTION: This antiosteoporotic agent is obtained by including a material obtained by pulverizing fish scale, e.g. obtained from sardine, Pacific saury, sea bream, carp, etc., by wet and dry pulverization utilizing a pulverizer, an atomizer, a pin mill, a hammer mil, etc., as an active ingredient. The agent is administered in the form of the above powder or a conventional pharmaceutical preparation obtained by mixing the active ingredient with a non-toxic carrier (e.g. glucose) for medicines suitable for oral administration. The daily dose of the active ingredient is e.g. about 1-1,000mg/kg body weight and properly determined by patient age, symptom, level of diseases, administration schedule, form, etc., of preparation.
The invention discloses a long-acting disinfection paste, which belongs to the field of skin and vaginal disinfectors, and is characterized by being formed by mixing polyvivyl pyrrolidone iodine, water soluble high polymers without side effects, an auxiliary agent and water in a certain ratio. In the product, the content of effective iodine is one time higher than that required by relative national standards, so that the disinfecting and sterilizing capability of the product is greatly improved, and the adverse reactions are avoided. The product can form a film on the skin surface to be adhered to the skin to avoid being rubbed out, thereby prolonging the disinfecting and sterilizing time by several times and offering a long-acting effect. The product can be used for treating small bleeding wounds without causing adverse reactions. The product has certain effects of treating skin abscesses, sores and furuncles and preventing the transmission of venereal diseases and AIDS. The product has the advantages of simple production equipment and process and high production efficiency. The result of many years of actual use shows that the product has a remarkable effect and is expected to replace various iodine disinfectors sold in the market presently.
FIELD: medicine, cosmetology, pharmacy. SUBSTANCE: invention proposes cosmetic or dermatological composition in the form of an aqueous and stable dispersion of cubic gel particles on the basis of 3,7,11,15-tetramethylhexadecane-1,2,3-triol or phytanetriol and its using for hydration (wetting) of skin. The composition has 0.1-15 wt.-% of 3,7,11,15-tetramethylhexadecane-1,2,3-triol as measured for total mass of composition and 0.1-3 wt.-% of dispersing and stabilizing agent as measured for total mass of composition. The agent is taken among water-soluble at the room temperature surface-active substances containing saturated or unsaturated aliphatic chain consisting of 8-22 carbon atoms. This composition ensures to include hydrophilic and/or lipophilic active components without any technical difficulties. EFFECT: enhanced effectiveness of composition. 31 cl, 1 tbl, 6 ex
Standard ERP will be performed to cannulate the PD, perform pancreatic sphincterotomy, and stricture dilation as necessary. A pancreatoscope (Spyglass Digital System, Boston Scientific, Marlborough, MA) will then be inserted through the duodenoscope into the PD. For PPL, electrical pulses will be delivered through an aqueous medium by EHL or LL with the probe tip in contact with or 1-2mm away from the stone. Settings for EHL (1.9F fiber; Autolith, Northgate Technologies, Elgin, IL) are 10-20 pulses/second with a power of 50-100; and for LL (200, 272, or 365 micrometer fiber, Versa Pulse Power Suite 20-W Holmium laser, New Star, Roseville, CA) ranging from 0.8 - 2.5 Joules with a frequency of 8-15Hz and power of 9-30 W. A maximum of 1 hour of intraductal lithotripsy will be allowed to reduce performance bias.
The present invention provides devices for dispensing topical pharmaceutical compositions. In some embodiments, the dispensing device possesses a reservoir for storing the composition and means for metering the composition. In some embodiments, such reservoirs are: i. made from, or substantially lined with, a material that opaque and/or substantially nondepleting of at least one component of the composition; ii. optionally, volumetrically compressible; and iii. fitted with the means for metering the composition. And the means for metering are adapted to measure a fixed amount of the composition for application to a dermal region of a user of the device. In some embodiments, the compositions has a specific gravity in the range of from about 0.85 to about 1.20 at about room temperature and comprises a medicament; a thickening agent; and a solvent, and optionally a skin penetration enhancer and/or a deodorant.
Sotalol hydrochloride tablets (AF) are a medicine that is given to patients with atrial fibrillation (irregular heartbeats). Atrial fibrillation happens when certain parts of the heart (the chambers known as atria) beat too fast or irregularly. When this happens, your heart cannot pump blood through your body as well as it should. This may make you feel weak and tired, or get out of breath easily. You may get an uncomfortable feeling in your chest and "fluttering" or "palpitations." Atrial fibrillation can be changed back (converted) to normal heart rhythm by an electric shock or by using certain medicines. However, atrial fibrillation can return. Sotalol hydrochloride tablets (AF) may help your heart stay beating regularly for a longer period of time.

This information about sotalol hydrochloride tablets (AF) was developed to ensure that you and your doctor get the right information about your type of irregular heartbeats. Consult your doctor before you accept any other sotalol product that does not provide this patient information.
Sham Comparator. It will received a light intensity shockwave in the lateral epicondyle regulated until reach a 3/10 in the Visual Analog Scale (VAS) scale.
INTRODUCTION: Small for gestational age (SGA) infants are at increased risk of fetal distress in labour requiring emergency operative birth (by caesarean section (CS), vacuum or forceps). We have previously shown that maternal oral sildenafil citrate (SC) in labour halves the need for operative birth for suspected fetal distress in women with appropriately grown term infants.
METHODS AND ANALYSIS: RidStress 2 is a phase III randomised, double-blinded, placebo-controlled trial of 660 women with an SGA or suboptimally grown fetus (estimated fetal weight or abdominal circumference<10th centile for gestational age) planning a vaginal birth at term. The trial will determine whether oral intrapartum SC (50 mg eight hourly) reduces the relative risk of emergency CS for fetal distress compared with placebo. The primary outcome is CS for fetal distress, and the secondary outcomes are any operative birth for fetal distress, cost-effectiveness of SC treatment and 2-year childhood neurodevelopmental outcomes. To detect a 33% reduction in the primary outcome from 30% to 20% for an alpha of 0.05 and power of 80% with 10% dropout, requires approximately 660 women (330 in each arm). This sample size will also yield >90% power to detect a similar reduction for the secondary outcome of any operative birth (CS or instrumental vaginal birth) for fetal distress.
ETHICS AND DISSEMINATION: Ethics approval was granted by the Mater Misericordiae Limited Human Research Ethics Committee (EC00332) on 11 September 2020. We plan to disseminate the results of this randomised controlled trial through presentations at scientific meetings and peer-reviewed journals, adhering to all relevant reporting guidelines.
TRIAL REGISTRATION NUMBER: RidStress 2 is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12621000354886, 29/03/2021) and the Therapeutic Goods Association of Australia (date registered: 16 March 2021).
Each subject can undergo to up to 3 blood draws; at the time of enrollment (T0), at 6 months (T1) and 12 months (T2) from diabetes diagnosis. After 24 months from diabetes diagnosis, a review of the electronic medical records (EMR) will be performed for all subjects with a "not detected" test result.
Background: Poor sleep quality affect students' learning achievement. Several factors may cause sleep disturbance among nursing students. Sleep and its several influencing factors are both continuous dynamic process. However, changes in students' sleep patterns and related characteristics over time remain unclear. Therefore, understanding the issue and examining an effective program is important to ameliorate sleep and improve learning. Integrated care program has proved to be a nursing students' health promotion intervention. However, research related to sleep and related issue in nursing students in a longitudinal manner is limited worldwide. Thus, the investigators intend to conduct a 3-year research divided into three phases to explore the issue. Objectives: The first phase will adopt longitudinal panel study design. Nursing students from two schools will be invited to participate in the first year study, which will be about 800 people.The data will be obtained from 4 waves (the interval of each wave will be 2 months) of the longitudinal survey of sleep quality of the nursing students and how the students' characteristics influence sleep. Distinct patterns of sleep over time will help to identify what characteristics of students to target for the researchers and to make evidence-based intervention for them. The second phase is to classify music appreciated by the students that may be effective and can be used at the third phase. The third phase is designed to explore the longitudinal effects of a 3-month social network combined with music care program on sleep quality, sleep knowledge, sleep hygiene and daytime sleepiness and fatigue. 100 students will be randomized into 2 groups: intervention and control groups. Participants in the intervention group will receive a 12-week intervention program. The control group will be no intervention. Data will be collected from both groups at pretests, and at different time points depending on variables after intervention completed. Statistical analysis: Growth curve modeling will be employed in this study for longitudinal analyses to identify the trajectory of sleep predicted by the students' characteristics. Descriptive analyses will be conducted using SPSS 18. Anticipated results and implications: This study will enable us to advance knowledge and research about nursing students' longitudinal patterns of sleep and the longitudinal effects of the intervention program on their sleep. If the longitudinal effects of the intervention program on their sleep are confirmed, the findings will provide evidence for educators and policy makers using evidence-based intervention to ameliorate sleep in nursing students.
Gastric cancer (GC) is the fourth most common cancer, and the second leading cause of cancer-related death worldwide. Advances in diagnostic and therapeutic approaches have achieved long-term survival for early GC. However, receiving perioperative/postoperative systemic chemotherapy and gastrectomy with D1-D2 lymph node dissection, 5-year survival rates of advanced gastric cancer remain under 30%. 40-60% of recurrences are peritoneal and/or locoregional. hyperthermic intraperitoneal chemotherapy (HIPEC) technique is increasingly used in the curative treatment of primary and digestive peritoneal carcinomatosis, in association with cytoreductive surgery. Theoretically, HIPEC eliminates free cancer cells that can be released into peritoneal cavity during the gastrectomy and prevents peritoneal carcinomatosis recurrences. The benefit of using HIPEC as an adjuvant treatment for advanced gastric cancer has been reported in several randomized studies and a meta-analysis. Surgical resection combined with HIPEC significantly reduces the peritoneal recurrences and improves the overall survival of GC patients. But there is not a prospective and randomized phase III clinical study of HIPEC in the treatment of locally advanced gastric cancer after radical surgery in China so far.

In order to evaluate the survival benefit and safety of radical surgery and HIPEC followed by postoperative chemotherapy in local advanced gastric cancer, patients who fulfill the inclusion and exclusion criteria will be recruited in this study and randomized to two treatment groups (HIPEC group and control group). In HIPEC group, the patients undergo radical gastrectomy with D2 lymphadenectomy and HIPEC with paclitaxel and postoperative chemotherapy. Patients in the control group just undergo radical gastrectomy with D2 lymphadenectomy followed by postoperative chemotherapy. Patients in both groups receive 6-8 cycles of postoperative systemic chemotherapy (XELOX or SOX regimens) . Patients are followed up for 5 years and the survival outcome will be analyzed.
Age matched controls for the various clinical groups will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi (millicurie) of 18F (fluorodeoxyglucose) -FDG prior to PET MRI, using "Biograph mMR" PET-MR (3T).
The present invention provides recombinant CEA glycoproteins and methods for their production. These recombinant CEA glycoproteins s lack the C-terminal 26 amino acids which are present in natural CEA and are characterized in that they are free from cross-reactive CEA-like antigens, antigenically indistingiushable from the soluble form of CEA shed from tumor cells, and devoid of the ethanolamine which is present at the C-terminus of natural CEA, and also devoid of the additional amino acids which may be attached to the natural CEA through said ethanolamine. Said recombinant CEA glycoproteins s preferably have the amino acid sequence SEQ ID NO: 1. The CEA glycoproteins s of the invention may be used as reagents in an immunoassay for the diagnosis of neoplastic diseases. The invention also relates to a DNA encoding said recombinant CEA glycoprotein, such as the DNA having the nucleotide sequence SEQ ID NO: 2 or a functional equivalent sequence thereof. The present invention also relates to recombinant vectors comprising said DNA, which recombinant vector is capable of directing the expression of said DNA in a compatible host cell, and to transformed host cells containing such a recombinant vector. The recombinant CEA glycoprotein of the present invention, preferably integrated in a test-kit, may be used for determining the presence of tumor cells in a sample of body fluid.